Skip to main content

Cholinergic Agonists

Cholinergic agonists are parasympathomimetics that stimulate muscarinic receptors on the detrusor smooth muscle to enhance bladder contractility. Bethanechol chloride is FDA-approved for acute postoperative or postpartum non-obstructive urinary retention and neurogenic atony of the bladder with retention.[2] It continues to be prescribed (in a US national survey of women's visits, mostly by urologists), but the underlying clinical evidence is low-quality, and contemporary reviews regard muscarinic agonists as having limited efficacy and frequent adverse effects for detrusor underactivity.[1][2][3][4]

For the clinical condition this drug class targets, see Underactive Bladder. For the antimuscarinic side of the same receptor system used in storage / OAB, see Anticholinergics.

Pharmacologic Framework — Cholinergic Control of the Bladder​

Muscarinic receptor physiology​

Normal voiding is initiated by parasympathetic release of acetylcholine (ACh) from pelvic nerves onto the detrusor. The bladder's cholinergic system is more complex than simple "ACh causes contraction"; multiple receptor subtypes operate at multiple sites, which is part of why agonist therapy is unpredictable in practice.[5][6][7][8]

Site / receptorRole
M₃ — detrusor smooth musclePrincipal driver of direct contraction (PLC, voltage-gated Ca²⁺, Rho kinase)
M₂ — detrusor smooth muscleMost abundant subtype (71% of receptors in sampled human detrusor membranes)[20]; indirect / backup role; opposes β-adrenergic relaxation; gains importance with denervation and aging
M₁ — prejunctional nerve terminalsFacilitate ACh release (positive feedback)
M₄ — prejunctional nerve terminalsInhibit ACh and noradrenaline release (negative feedback)
Urothelial muscarinic receptorsStimulate ATP and NO release that modulates afferent activity and reflex voiding
Suburothelial interstitial cellsExpress muscarinic receptors of unknown function

This anatomic complexity explains why direct muscarinic agonists simultaneously stimulate contraction, modulate sensory pathways, and alter neurotransmitter release, and why their clinical effect on a clogged or weak bladder is far less reliable than benchtop pharmacology suggests.[5]

Two classes used (or studied) in urology​

ClassAgentsMechanism
Direct muscarinic agonistsBethanechol (FDA-approved); carbachol, pilocarpine (historical / non-urologic)Direct muscarinic-receptor stimulation; resistant to cholinesterase[2][3][5]
Cholinesterase inhibitors (indirect)Distigmine, neostigmine, pyridostigmineInhibit ACh breakdown → increased synaptic ACh[5][9][10][11][12][13][14]

Bethanechol Chloride — the primary urologic agent​

Pharmacology[2]​

A synthetic choline ester structurally related to ACh with three useful properties:

  1. Cholinesterase-resistant. Not hydrolyzed, giving a longer duration than ACh
  2. Muscarinic-selective. At therapeutic doses, nicotinic effects (ganglionic stimulation, skeletal muscle contraction) are minimal; muscarinic effects predominate
  3. Does not cross the blood–brain barrier. Quaternary amine; no CNS effects

Pharmacokinetics:

  • Oral. Onset 30–90 min; peak 60–90 min; duration about 1 h (up to 6 h with large doses)
  • SC. Onset 5–15 min; peak 15–30 min; duration about 2 h
  • Route comparison in urinary retention: In a study of bladder stretch response, 5 mg SC produced a faster and larger response than 50–200 mg oral; the oral response lasted longer.[2]
  • Metabolic fate and excretion not fully elucidated

SC bethanechol is no longer commonly stocked in the US. The oral tablet is the practical formulation.

FDA-approved indications[2]​

  1. Acute postoperative and postpartum non-obstructive (functional) urinary retention
  2. Neurogenic atony of the urinary bladder with retention

Dosing[2]​

  • Oral: 10–50 mg three or four times daily[2]
  • Titration: start 5–10 mg; repeat the same dose at hourly intervals until satisfactory response or a total of 50 mg has been given in that dose-finding sequence; this is not permission to add a separate 50-mg dose afterward[2]
  • Take on an empty stomach (1 h before or 2 h after meals) to limit nausea / vomiting
  • Suspected overdose warrants urgent medical assessment. The label identifies atropine sulfate as an antidote, with repeat dosing guided by clinical response; see the product label and emergency or toxicology protocol.[2]

Contraindications[2]​

Bethanechol is contraindicated in mechanical or bladder-neck obstruction. If the sphincter fails to relax during detrusor contraction, urine may reflux into the upper tract; with bacteriuria, reflux infection may result.[2] Bethanechol given with ganglion-blocking compounds can cause a critical fall in blood pressure.[2]

Other formal label contraindications:[2]

  • Bladder outlet obstruction or any mechanical obstruction
  • Hypersensitivity to bethanechol
  • Recent bladder surgery or compromised bladder-wall integrity
  • Recent GI surgery, resection / anastomosis, or obstruction
  • Hyperthyroidism, peptic ulcer disease
  • Latent or active asthma (explicit label contraindication); other significant respiratory disease warrants clinical assessment[2]
  • Pronounced bradycardia or hypotension; vasomotor instability
  • Coronary artery disease
  • Epilepsy, parkinsonism
  • Marked vagotonia
  • Spastic GI disorders, acute inflammatory GI lesions, peritonitis

Adverse effects[2]​

Adverse effects are uncommon at oral therapeutic doses but common with parenteral or supratherapeutic dosing. The pattern is the classic muscarinic (SLUDGE) response:

DomainEffects
GINausea, vomiting, abdominal cramping, diarrhea, salivation, belching, borborygmi
CardiovascularHypotension with reflex tachycardia, flushing, sweating
RespiratoryBronchospasm, asthma exacerbation
GenitourinaryUrgency; reflux into the kidneys if used despite outlet obstruction
EyeLacrimation, miosis
SkinDiaphoresis

Severe overdose can produce circulatory collapse, sudden hypotension, syncope, or cholinergic crisis, requiring urgent airway and cardiovascular assessment and atropine directed by clinical response and a toxicology protocol.[2]

Cholinesterase Inhibitors​

Indirect cholinergic agents have been studied for detrusor underactivity, primarily in Japan and Europe; none is FDA-approved for urologic use in the US.[5][10][11][12][13][14]

AgentStatusNotes
Distigmine bromideUsed in Japan / Europe for atonic bladderLong anticholinesterase action; potentiates ACh-induced detrusor contraction; risk of cholinergic crisis[11][12][13]
Neostigmine, pyridostigmineOff-label / historicalNeostigmine has historical use for postoperative ileus and atonic bladder. In a 2025 placebo-controlled trial after TURP in men with preoperative low bladder contractility, postoperative retention occurred in 3/34 given pyridostigmine versus 12/32 given placebo over three months (73 randomized, 66 analyzed), and adverse effects were reported in 8/34 versus 1/32; benefit beyond three months remains uncertain.[19]
TAK-802 (investigational)Selective AChE inhibitorImproved urodynamic parameters in animal models; not in clinical use[14]

In practice these agents are not part of contemporary US urologic prescribing.

Evidence Summary​

SettingEvidenceResult
Established postoperative urinary retention (any drug, any sex)Cochrane review (Buckley & Lapitan)[9]Seven studies (494 adults) evaluated treatment after retention developed. Cholinergic agents, alpha-blockers and sedatives as monotherapies did not show a significant treatment benefit; overall drug-treatment evidence was weak
Underactive bladder — direct muscarinic agonists ± AChE inhibitorsSystematic review and meta-analysis (Moro et al.)[3]Twelve controlled trials (10 randomized, two nonrandomized; n = 3,024), with median follow-up of 18 hours among ten reporting studies. In two perioperative studies (n = 400), postoperative urinary retention was lower at 12–36 hours with treatment (RR 0.55, 95% CI 0.30–0.98; low certainty). Overall PVR was not significantly different; it was lower within one week (MD −77.5 mL) but not significantly different at one month. Adverse events were not significantly different.
Underactive bladder — earlier systematic reviewBarendrecht et al. (10 RCTs)[16]3 studies improved, 6 showed no difference, 1 worsened; data do not support use, particularly given the adverse-effect profile
General lower-tract pharmacotherapy reviewAbraham & Goldman update[10]Muscarinic agonists have limited efficacy in detrusor underactivity; prescribing should be individualized
Detrusor underactivity overviewDrake et al. Nat Rev Urol[4]Current treatments have poor efficacy and tolerability; muscarinic agonists in particular have limited efficacy and frequent adverse effects. Intermittent or indwelling catheterization may achieve emptying, and sacral nerve stimulation may reduce catheter dependence
Real-world prescribingGaitonde et al., NAMCS 2003–2013, women only[1]Bethanechol was prescribed at 0.8% of weighted visits for LUTS, neurogenic bladder or retention; 92% of prescription visits were with urologists, and 79% were for continued medication (mean age 62)

Guidelines advise against routine use. EAU Neuro-Urology 2026 makes a strong recommendation not to prescribe parasympathomimetics for underactive detrusor; EAU Non-neurogenic Female LUTS 2026 makes a strong recommendation against routine use in women with underactive bladder; the EAU male LUTS guideline takes the same position for men (strong; level 4 evidence). The EAU male LUTS guideline cites Moro et al.'s meta-analysis of 12 controlled trials (10 randomized, two nonrandomized) in men and women with underactive bladder. In two perioperative studies (n = 400), post-procedure urinary retention was lower, while overall PVR and adverse-event differences were not statistically significant; median follow-up among ten reporting trials was 18 hours.[3][15][17][18] A historic label indication does not establish durable efficacy or justify delaying bladder drainage.[3][4]

Clinical Positioning​

  • Confirm non-obstructive retention before prescribing. Consider BPH, urethral stricture, and bladder-neck dysfunction; examination and indicated cystoscopy or RUG assess anatomy, while PVR and uroflow assess emptying. When detrusor underactivity and outlet obstruction both remain plausible, pressure-flow urodynamics distinguishes them.[15][18] Mechanical or bladder-neck obstruction is a label contraindication.[2]
  • Treat outlet nonrelaxation separately. Bethanechol is contraindicated in bladder-neck obstruction; an unrelaxed sphincter also raises the label’s upper-tract reflux concern.[2] Maintain bladder drainage when needed and address bladder-neck resistance with alpha-blockers or DSD with sphincter-directed treatment, as appropriate.[10][17] In neuro-urological patients, EAU strongly recommends alpha-blockers to decrease outlet resistance and strongly recommends against parasympathomimetics for underactive detrusor.[17]
  • Acute postoperative or postpartum nonobstructive retention is a labeled indication; assess the need for drainage promptly. Recent bladder or GI reconstruction may itself make bethanechol unsafe, and it is not a routine substitute for catheterization.[2][9] For a patient who is breastfeeding, the label states that milk transfer is unknown and advises deciding whether to stop nursing or stop the drug in view of potential serious infant reactions.[2]
  • CIC is the cornerstone of chronic detrusor underactivity; pharmacotherapy is adjunctive at best.[4]
  • Avoid in older adults with cardiopulmonary disease. The AE profile (bronchospasm, bradycardia, hypotension, GI cramping) is particularly poorly tolerated.[2]
  • Counsel about cholinergic side effects (flushing, sweating, salivation, abdominal cramps, diarrhea) and about taking on an empty stomach.[2]

Practical Pearls​

  • Exclude outlet obstruction before bethanechol. If sphincter relaxation fails, the label warns that upper-tract reflux may occur and bacteriuria may lead to reflux infection.[2]
  • Effects are modest and inconsistent. Set expectations accordingly with patients[1][3][4]
  • Empty stomach dosing reduces GI side effects substantially[2]
  • Suspected cholinergic toxicity requires urgent assessment; atropine treats muscarinic effects, with resuscitation and individualized dosing as needed[2]
  • CIC provides reliable emptying when required; there is no established drug that restores normal voiding consistently[4]
  • Cholinesterase inhibitors are not part of US urologic practice. Distigmine remains a Japanese or European option but is not commonly used[10][11][12]

See Also​

References​

1. Gaitonde S, Malik RD, Christie AL, Zimmern PE. "Bethanechol: is it still being prescribed for bladder dysfunction in women?" Int J Clin Pract. 2019;73(8):e13248. doi:10.1111/ijcp.13248

2. Bethanechol chloride tablets: US prescribing information. DailyMed, updated January 29, 2026. Label.

3. Moro C, Phelps C, Veer V, et al. "The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta-analysis." Neurourol Urodyn. 2022;41(1):127–139. doi:10.1002/nau.24839

4. Drake MJ, Williams J, Bijos DA. "Voiding dysfunction due to detrusor underactivity: an overview." Nat Rev Urol. 2014;11(8):454–464. doi:10.1038/nrurol.2014.156

5. Sellers DJ, Chess-Williams R. "Muscarinic agonists and antagonists: effects on the urinary bladder." Handb Exp Pharmacol. 2012;(208):375–400. doi:10.1007/978-3-642-23274-9_16

6. Frazier EP, Peters SL, Braverman AS, Ruggieri MR, Michel MC. "Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors." Naunyn Schmiedebergs Arch Pharmacol. 2008;377(4-6):449–462. doi:10.1007/s00210-007-0208-0

7. Choppin A, Eglen RM. "Pharmacological characterization of muscarinic receptors in mouse isolated urinary bladder smooth muscle." Br J Pharmacol. 2001;133(7):1035–1040. doi:10.1038/sj.bjp.0704165

8. Kullmann FA, Artim DE, Birder LA, de Groat WC. "Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity." J Neurosci. 2008;28(8):1977–1987. doi:10.1523/JNEUROSCI.4694-07.2008

9. Buckley BS, Lapitan MC. "Drugs for treatment of urinary retention after surgery in adults." Cochrane Database Syst Rev. 2010;(10):CD008023. doi:10.1002/14651858.CD008023.pub2

10. Abraham N, Goldman HB. "An update on the pharmacotherapy for lower urinary tract dysfunction." Expert Opin Pharmacother. 2015;16(1):79–93. doi:10.1517/14656566.2015.977253

11. Obara K, Kobayashi Y, Chino D, Tanaka Y. "Effect of distigmine on the contractile response of guinea pig urinary bladder to electrical field stimulation." Eur J Pharmacol. 2017;809:209–214. doi:10.1016/j.ejphar.2017.05.031

12. Obara K, Ogawa T, Chino D, Tanaka Y. "The long-lasting enhancing effect of distigmine on acetylcholine-induced contraction of guinea pig detrusor smooth muscle correlates with its anticholinesterase activity." Biol Pharm Bull. 2017;40(7):1092–1100. doi:10.1248/bpb.b17-00175

13. Obara K, Tanaka Y. "Effects of distigmine on the mechanical activity of urinary bladder smooth muscle." Biol Pharm Bull. 2019;42(7):1064–1068. doi:10.1248/bpb.b19-00201

14. Nagabukuro H, Okanishi S, Doi T. "Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs." Eur J Pharmacol. 2004;494(2-3):225–232. doi:10.1016/j.ejphar.2004.05.007

15. EAU. Management of non-neurogenic male LUTS: disease management, section 5.7, underactive bladder. 2026. Guideline.

16. Barendrecht MM, Oelke M, Laguna MP, Michel MC. "Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?" BJU Int. 2007;99(4):749–752. doi:10.1111/j.1464-410X.2006.06742.x

17. EAU. Neuro-Urology, limited update March 2026: pharmacological treatment recommendations. Guideline.

18. EAU. Management of Non-neurogenic Female LUTS, limited update March 2026: section 4.4.4.b.1 (parasympathomimetics). Guideline.

19. Zeinelabden KM, El-Shazly M, Alorabi A, Kandeel H, Salman B, Aziz M. "The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder: prospective randomized trial." World J Urol. 2025;43(1):473. doi:10.1007/s00345-025-05842-8

20. Mansfield KJ, Liu L, Mitchelson FJ, et al. "Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing." Br J Pharmacol. 2005;144(8):1089–1099. doi:10.1038/sj.bjp.0706147